FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAmgen Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AMGN
Amgen Inc. Stock AnalysisComprehensive stock analysis for Amgen Inc. (AMGN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAMGN
AMGN
Amgen Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AMGN
  1. Home
  2. Stocks
  3. Amgen Inc.

Amgen Inc.

🇺🇸AMGN•NASDAQ

Amgen Inc.

🇺🇸AMGN•NASDAQ
Market cap
$250.07B
Sentiment

Your view on AMGN

Mkt Cap
$250.07B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Amgen Inc.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Robert A. Bradway
Headquarters
One Amgen Center Drive, Thousand Oaks, CA, US
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Robert A. Bradway
Headquarters
One Amgen Center Drive, Thousand Oaks, CA, US
Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.

It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer.

It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Amgen Inc. from FRC's valuation model, read against the market price. AMGN last traded at $462.32, 26.6× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Amgen Inc.. Starting points for Amgen Inc.: P/E 26.6, EPS $17.36, beta 0.42 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Amgen Inc.. Amgen Inc. paid $9.94 per share over the last year — a 2.2% yield at the current $462.32 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Amgen Inc.. Trailing twelve-month EPS for Amgen Inc. stands at $17.36. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$423.13

average of 23 firms, last 12 months

 

$423.13

Low $230.00

Median $425.00

High $531.00

 

Analyst Ratings

Hold25 firms, last 12 months
  • Strong Buy0
  • Buy8
  • Hold15
  • Sell2
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$5.63$5.71$23.55$25.07
Low estimate$5.21$5.40$23.20$23.54
High estimate$6.12$6.04$24.15$26.59
No. of analysts1861920
Year-ago EPS$5.29$5.15$14.23—
Growth+6.4%+10.9%+65.5%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$10.45B$9.56B$39.46B$41.29B
Low estimate$10.33B$9.22B$39.03B$40.37B
High estimate$10.54B$10.26B$39.89B$42.42B
No. of analysts1552324
Year-ago revenue$9.87B$8.62B$36.74B—
Growth+6.0%+10.9%+7.4%—
Recent analyst actions15 rating and price-target changes, latest Nov 12, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, MarketWatch; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Amgen Inc.. Amgen Inc. has reported as a listed company since 1983. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AMGN20 companies · 8 funds
Compare AMGN with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABBVAbbVie Inc.Drug Manufacturers - General$520.9B
  • AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
  • BMYBristol-Myers Squibb CompanyDrug Manufacturers - General$128.6B
  • GSKGSK plcDrug Manufacturers - General$97.5B
  • JNJJohnson & JohnsonDrug Manufacturers - General$687.9B
  • LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
  • MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B
  • NVSNovartis AGDrug Manufacturers - General$302.6B

More Drug Manufacturers - General companies

  • OPHLFOno Pharmaceutical Co., Ltd.OTC$7.8B
  • OPHLYOno Pharmaceutical Co., Ltd.OTC$7.9B
  • ORINFOrion OyjOTC$11.1B
  • ORINYOrion OyjOTC$22.8B
  • OTSKFOtsuka Holdings Co., Ltd.OTC$35.4B
  • OTSKYOtsuka Holdings Co., Ltd.OTC$36.6B
  • PFEPfizer Inc.NYSE$159.9B
  • PFE.NEPfizer Inc.NEO
  • PTKFFPT Kalbe Farma Tbk.OTC$3.2B
  • PTKFYPT Kalbe Farma Tbk.OTC$15M
  • RHHBFRoche Holding AGOTC$390.8B
  • RHHBYRoche Holding AGOTC$383.1B

ETFs holding Amgen Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.39%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.35%
  • QQQInvesco QQQ Trust, Series 1$446.1B in assets1.17%
  • SCHDSchwab U.S. Dividend Equity ETF$119.9B in assets4.08%
  • BBHVanEck Biotech ETF$536M in assets16.87%
  • IBBiShares Biotechnology ETF$11.1B in assets8.58%
  • DIVOAmplify CWP Enhanced Dividend Income ETF$7.9B in assets5.77%
  • HHL.TOHarvest Healthcare Leaders Income ETF$2.2B in assets4.80%

Largest holders first, then the funds most concentrated in AMGN.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Amgen Inc., and how their positions are changing. At a $250.07B market value, institutional positions materially move Amgen Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Amgen Inc. executives and directors. Shares of Amgen Inc. have traded between $253.30 and $345.84 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Amgen Inc.. Amgen Inc. is a $250.07B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Amgen Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Amgen Inc.. Coverage tracks Amgen Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Amgen Inc.

AMGN Analysis
Good
Past4
Growth4
Health2
Profit5
Value1

News

Latest Market News